$VKTX news
The latest VKTX stock news: headlines, filings, AI summaries and sentiment for $VKTX, updated around the clock.
- Eli Lilly Raises Revenue Forecast Amid Strong Zepbound Sales and Competition from Viking Therapeutics
- Verastem Reports Q3 2026 Revenue Growth and Positive Clinical Data for VS-7375
- Rhythm Pharmaceuticals Reports Q3 2026 Revenue Growth Driven by Acquired Hypothalamic Obesity Treatments
- UBS Initiates Coverage on Viking Therapeutics with Buy Rating and $94 Price Target
- Viking Therapeutics, Inc. - 10-Q Filing
- Viking Therapeutics Reports Q3 2026 Financial Results and Positive Obesity Pipeline Data
- Viking Therapeutics Outlines $100 Million Average Quarterly Cash Burn Amid Clinical Pipeline Advancement
- Viking Therapeutics Reports Increased Q3 Net Loss Driven by Rising R&D Expenses
- Viking Therapeutics Reports Q3 GAAP EPS of -$1.55, Missing Estimates by $0.50
- Viking Therapeutics, Inc. - 8-K Filing
- Viking Therapeutics Initiates Phase 3 Trials for Oral Weight Loss Drug VK2735
- Four High-Risk Stocks With Potential for Significant Returns
- Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing
- Viking Therapeutics Stock Falls Below $35 IPO Price Amid Dilution Concerns
- Viking Therapeutics Shares Rise Over 30% on Encouraging Weight-Loss Drug Trial Results
- Eli Lilly's Stock Unaffected by Viking Therapeutics' Strong Clinical Results
- Viking Therapeutics, Inc. - 8-K Filing
- Viking Therapeutics Reports Positive VK2735 Maintenance Trial Results but Faces Oral Formulation Challenges
- Viking Therapeutics Reports Strong Weight-Loss Drug Trial Results
- Viking Therapeutics Shares Drop After Oversubscribed Capital Raise
- Viking Therapeutics Announces $500M Public Offering
- Biggest Stock Movers on Thursday Include P, VKTX, and MGM
- Viking Therapeutics Shares Rise Over 35% After Positive Weight Loss Drug Trial Results
- Viking Therapeutics Announces Positive Phase 2 Trial Results for VK2735
- Viking Therapeutics Files for Combined $400 Million Offering
- Novo Nordisk CEO Considering Direct NYSE Listing for U.S. Investors
- Jaguar Health Drops 59%, Viking Therapeutics Falls 4%
- Viking Therapeutics Shares Surge After Positive Clinical Trial Results for Obesity Drug
- Viking Therapeutics' Obesity Drug Trial Results Spark Market Interest
- Viking Therapeutics Surges on Positive GLP-1 Maintenance Dosing Data
- Meta Partners With Shopify for AI-Driven Purchases After Amazon Blocks Muse
- Viking Therapeutics Shares Rise on Positive Obesity Drug Trial Results
- Viking Therapeutics Shares Rise on Positive Obesity Drug Data
- Viking Therapeutics Shares Rise on Positive Obesity Drug Data; Rivals See Decline
- Viking Therapeutics, Inc. - 8-K Filing
- Novo Nordisk Shares Drop as Post-Wegovy Growth Strategy Fails to Alleviate Competition Concerns
- Vertex Acquires Crinetics for $10 Billion; Viking Therapeutics Seen as Potential Next Target
- Viking Therapeutics Advances Phase III Trials for VK2735 in Obesity
- Viking Therapeutics, Inc. - 10-Q Filing
- Viking Therapeutics, Inc. - 8-K Filing
- Viking Therapeutics Announces Phase 1 Trial for Weight Loss Drug Targeting Amylin and Calcitonin Pathways
- Eli Lilly Announces Approval for New Oral Weight Loss Drug
- Amazon Launches GLP-1 Weight Loss Program to Simplify Access to Obesity Treatments